| Summary of significant segment expenses and segment net loss |
The following table summarizes our significant segment expenses and segment net loss for the three and six months ended June 30, 2025 and 2024 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended June 30, |
|
|
For the six months ended June 30, |
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
Expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Canvuparatide direct program expense |
|
$ |
8,923 |
|
|
$ |
4,980 |
|
|
$ |
17,260 |
|
|
$ |
8,963 |
|
Imapextide direct program expense |
|
|
987 |
|
|
|
5,108 |
|
|
|
2,793 |
|
|
|
7,744 |
|
MBX 4291 direct program expense |
|
|
2,547 |
|
|
|
1,521 |
|
|
|
8,322 |
|
|
|
2,145 |
|
Preclinical and other research and development direct expense |
|
|
1,641 |
|
|
|
358 |
|
|
|
2,850 |
|
|
|
575 |
|
Research and development overhead expense |
|
|
3,626 |
|
|
|
2,429 |
|
|
|
8,905 |
|
|
|
6,018 |
|
Other segment items (1) |
|
|
1,687 |
|
|
|
1,461 |
|
|
|
3,161 |
|
|
|
2,749 |
|
Net loss |
|
$ |
19,411 |
|
|
$ |
15,857 |
|
|
$ |
43,291 |
|
|
$ |
28,194 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Other segment items are primarily comprised of general and administrative expenses and interest and other income.
|